William Blair Initiates Coverage On Immunome with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating.
Stocks · News reference
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Immunome Entered Amendment No. 4 To License Agreement With Bristol-Myers Squibb On October 2, 2026
8-K filing — Immunome Inc. (IMNM)
Filed: 2026-10-05 AccNo: 0001193125-26-413217 Size: 329 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24